Major Depressive Disorder | Treatment Algorithms: Claims Data Analysis | US | 2023
Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SNRIs), and—as adjunctive therapies—atypical antipsychotics. Although this drug market is ingrained with generic therapies, MDD patients’ heterogeneous response to current drugs and the need for additional efficacious therapies give branded agents (e.g., Trintellix [Lundbeck / Takeda], Rexulti [Otsuka / Lundbeck], Spravato [Janssen]) the opportunity to be incorporated into the treatment algorithm. Given MDD’s highly competitive landscape encompassing both long-established and newer-to-market drugs, it is valuable for drug marketers and developers to understand physicians’ actual prescribing behavior in MDD. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for MDD.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
- How have Trintellix, Rexulti, and Spravato been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of MDD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of MDD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States.
Key companies: Lundbeck, Otsuka, Takeda, Janssen, Sunovion, AbbVie.
Key drugs: Trintellix, Rexulti, Latuda, Vraylar, Spravato, citalopram, escitalopram, fluoxetine, sertraline, duloxetine, venlafaxine, aripiprazole, quetiapine, bupropion hydrochloride SR/XL, mirtazapine.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
